title: Direct treatment of fetal supraventricular tachycardia after failed transplacental therapy.
abstract: Digitalization by direct intramuscular injection of the fetus successfully controlled supraventricular tachycardia at 24 weeks' gestation after more traditional intensive trials of transplacental therapy with digoxin, verapamil, and procainamide, either separately or in combination, had failed. The fetal pharmacokinetics were calculated from fetal blood samples obtained by cordocentesis. No clear evidence of placental transfer of digoxin administered to the mother could be found despite a digoxin concentration in the mother that ranged from 1.8 to 2.6 ng/ml for 4 days. After direct fetal digitalization we calculated that the coefficient of elimination for digoxin from the fetus was 0.0463 h-1, and digoxin elimination half-life was 15.9 hours. The latter time span is substantially less than the 50-hour half-life previously reported in newborn infants with low birth weight. The fetal/maternal concentration ratio of procainamide was 0.914. However, maternal clearance of procainamide (9.7 ml/kg-1/min-1) was twice as long as the clearance reported for nonpregnant patients undergoing fast acetylation. We conclude first, that at least in the dose of this ill fetus, little digoxin administered to the mother crossed the placentae; and second, that while direct fetal therapy with digoxin is effective, the necessary frequent number of injections render this therapy impractical. Direct fetal digitalization should probably be reserved for the preterm fetus who has evidence of heart failure and has not responded to maternally administered therapy other than digoxin.
authors.affiliation: Department of Obstetrics and Gynecology, University of Iowa Medical School, Iowa City 52242.
authors.forename: C P
authors.initials: CP
authors.lastname: Weiner
authors.forename: M I
authors.initials: MI
authors.lastname: Thompson
mesh_terms: D000328:Adult; D004077:Digoxin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D005260:Female; D005315:Fetal Diseases / Q000188:drug therapy*; D005333:Fetus / Q000378:metabolism; D006801:Humans; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D011342:Procainamide / Q000627:therapeutic use; D013617:Tachycardia, Supraventricular / Q000188:drug therapy*
chemical_list: D004077:Digoxin; D011342:Procainamide